Millions of people are now using weight-loss drugs, but it seems there are side-effects that come with the slimmer waistlines ...

Glucagon-like peptide-1 receptor agonist drugs (commonly referred to as GLP-1 agonists) have become widely prescribed for ...

The FDA has granted breakthrough therapy designation to privosegtor for optic neuritis, a common symptom of multiple sclerosis.

Oculis, Legacy Healthcare and Neurosterix are advancing their drug pipelines with major clinical milestones. Oculis’ Privosegtor received breakthrough therapy designation from the U.S. Food and Drug ...

Oculis’ neuroprotective candidate privosegtor receives US FDA breakthrough therapy designation to treat optic neuritis: Zug, Switzerland Thursday, January 8, 2026, 17:00 Hrs [IS ...

Breakthrough therapy designation granted as Company advances the PIONEER registrational program in optic neuropathies to create a potential ...

Please provide your email address to receive an email when new articles are posted on . If approved, privosegtor would become the first neuroprotective therapy for optic neuropathies. The PIONEER 1 ...

The US Food and Drug Administration has granted breakthrough therapy designation to Oculis’ neuroprotective candidate ...

Breakthrough Therapy Designation granted to Privosegtor, a neuroprotective candidate, for the treatment of optic neuritis Privosegtor is advancing ...

Privosegtor is advancing in the registrational PIONEER program across 2 key optic neuropathies, representing an unaddressed potential market of $7 billion in the U.S. Privosegtor achieved an average ...

Another mass tort to watch in 2026 involves Bayer’s widely used weedkiller Roundup and allegations that its active ingredient, glyphosate, can cause cancer. Tens of thousands of plaintiffs have filed ...

Research unveiled more possible safety signals and benefits ...